The emergence of multiple drug resistant pathogens is becoming problematic worldwide, and the discovery of new antibiotics continues to decline. The broad, long-term objective of this proposal is to discover, characterize, and develop a new structural class of antibiotics-nucleoside antibiotics-that target bacterial translocase I involved in peptidoglycan cell wall biosynthesis.
The specific aims of this proposal are (I) to characterize the assembly and incorporation of the aminoribosyl moiety found within the family of lipopeptidyl-nucleoside antibiotics and (II) to functionally and mechanistically characterize enzymes catalyzing novel or unusual biochemical reactions represented herein by a new family of serine hydroxymethyltransferase-like enzymes that are hypothesized to catalyze an aldol-type condensation to form unusual nonproteinogenic amino acids.
Specific Aim I and II will be achieved by using the robust genetic system developed for the lipopeptidyl nucleoside A-90289-producing strain for in vivo studies employing gene inactivation and cross-complementation, and recombinant proteins will be exploited for functional and mechanistic studies in vitro. The results will establish a new mechanism for incorporating ribosyl units into natural product scaffolds and will establish a paradigm for the entry into high-carbon nucleoside antibiotics. The results will be essential for our long-term goals of searching for new nucleoside antibiotics using genetic information (a genotype-to-chemotype approach), will allow for the structural diversification of the parent scaffolds using combinatorial biosynthesis and total synthesis, and will provide the basis for the design of second generation antibiotics with improved biocompatibility and pharmacological properties.
Diseases caused by multidrug resistant bacteria are becoming a significant threat to human health worldwide. The goal of this proposal is to study nucleoside antibiotics that represent a new structural class of antibiotics, have a different mode of action than clinically used antibacterial drugs, and are in general not toxic to animals.
|Liu, Xiaodong; Jin, Yuanyuan; Cui, Zheng et al. (2016) The Role of a Nonribosomal Peptide Synthetase in l-Lysine Lactamization During Capuramycin Biosynthesis. Chembiochem 17:804-10|
|Cai, Wenlong; Wang, Xiachang; Elshahawi, Sherif I et al. (2016) Antibacterial and Cytotoxic Actinomycins Y6-Y9 and Zp from Streptomyces sp. Strain GÃ¶-GS12. J Nat Prod 79:2731-2739|
|Liu, Xiaodong; Jin, Yuanyuan; Cai, Wenlong et al. (2016) A biocatalytic approach to capuramycin analogues by exploiting a substrate permissive N-transacylase CapW. Org Biomol Chem 14:3956-62|
|Goswami, Anwesha; Van Lanen, Steven G (2015) Enzymatic strategies and biocatalysts for amide bond formation: tricks of the trade outside of the ribosome. Mol Biosyst 11:338-53|
|Kulkarni, Aditya; Zeng, Yu; Zhou, Wei et al. (2015) A Branch Point of Streptomyces Sulfur Amino Acid Metabolism Controls the Production of Albomycin. Appl Environ Microbiol 82:467-77|
|Cai, Wenlong; Goswami, Anwesha; Yang, Zhaoyong et al. (2015) The Biosynthesis of Capuramycin-type Antibiotics: IDENTIFICATION OF THE A-102395 BIOSYNTHETIC GENE CLUSTER, MECHANISM OF SELF-RESISTANCE, AND FORMATION OF URIDINE-5'-CARBOXAMIDE. J Biol Chem 290:13710-24|
|Bachmann, Brian O; Van Lanen, Steven G; Baltz, Richard H (2014) Microbial genome mining for accelerated natural products discovery: is a renaissance in the making? J Ind Microbiol Biotechnol 41:175-84|
|Chi, Xiuling; Baba, Satoshi; Tibrewal, Nidhi et al. (2013) The muraminomicin biosynthetic gene cluster and enzymatic formation of the 2-deoxyaminoribosyl appendage. Medchemcomm 4:239-243|
|Van Lanen, Steven G (2013) Biosynthesis: a sulfonate relay revealed. Nat Chem Biol 9:602-3|
|Funabashi, Masanori; Baba, Satoshi; Takatsu, Toshio et al. (2013) Structure-based gene targeting discovery of sphaerimicin, a bacterial translocase I inhibitor. Angew Chem Int Ed Engl 52:11607-11|
Showing the most recent 10 out of 14 publications